1. Home
  2. TG vs LYEL Comparison

TG vs LYEL Comparison

Compare TG & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tredegar Corporation

TG

Tredegar Corporation

N/A

Current Price

$5.58

Market Cap

239.6M

Sector

Industrials

ML Signal

N/A

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

N/A

Current Price

$14.43

Market Cap

195.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TG
LYEL
Founded
1988
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
239.6M
195.8M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
TG
LYEL
Price
$5.58
$14.43
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $38.38
AVG Volume (30 Days)
★ 273.7K
218.6K
Earning Date
11-06-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 151.06
N/A
EPS
★ 0.26
N/A
Revenue
★ $800,821,000.00
$36,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$21.79
★ N/A
Revenue Growth
★ 8.29
N/A
52 Week Low
$5.26
$7.20
52 Week High
$10.53
$45.00

Technical Indicators

Market Signals
Indicator
TG
LYEL
Relative Strength Index (RSI) 28.75 62.76
Support Level N/A $12.25
Resistance Level $8.15 $14.97
Average True Range (ATR) 0.42 1.58
MACD -0.19 0.45
Stochastic Oscillator 12.52 66.05

Price Performance

Historical Comparison
TG
LYEL

About TG Tredegar Corporation

Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: